title: Immunotherapy for the treatment of Hodgkin lymphoma.
abstract: Most patients with Hodgkin lymphoma (HL) enjoy durable remissions following front-line treatment but 30% of patients are refractory or relapse after first line therapy. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) can cure an additional 50-55% of relapsing patients but new treatments are needed for patients with HL who are refractory or relapse after ASCT. Immunotherapy has emerged as a promising treatment for the management of these patients. The availability of the anti-CD30 antibody brentuximab vedotin and new targeted drugs such as immune checkpoint inhibitors, show promising clinical activity in patients with HL and are important milestones for the management of patients with HL particularly for those who have progressed after standard initial therapy and ASCT. Areas covered: Overview of the results from the most relevant clinical trials including monoclonal antibody-based therapy in HL. Phase 2 and phase 3 trials including brentuximab vedotin and immune checkpoints inhibitors in patients with Hodgkin lymphoma have been reviewed. In addition, the potential impact of these new therapies in the management of patients with newly diagnosed HL has also been addressed. Expert commentary: Anti-CD30 antibody brentuximab vedotin and immune checkpoint inhibitors have shown promising results in patients with relapsed and refractory HL. Administration of these therapies earlier in the course of the disease might reduce the proportion of relapsed or refractory patients and, subsequently, minimize the number of patients undergoing high-dose therapy and autologous stem cell transplantation. We have little doubt that this will have substantial effects on the outcome for future generations of HL patients.
authors.affiliation: a Hematology Service , University Hospital Doctor Peset , Valencia , Spain.
authors.forename: Eva M
authors.initials: EM
authors.lastname: Donato
authors.affiliation: a Hematology Service , University Hospital Doctor Peset , Valencia , Spain.
authors.forename: Miguel
authors.initials: M
authors.lastname: Fernández-Zarzoso
authors.affiliation: a Hematology Service , University Hospital Doctor Peset , Valencia , Spain.|b Department of Internal Medicine , Universidad Católica de Valencia "San Vicente Mártir" , Valencia , Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: De La Rubia
mesh_terms: D064592:Autografts; D000079963:Brentuximab Vedotin; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006689:Hodgkin Disease / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D033581:Stem Cell Transplantation
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Hodgkin lymphoma; brentuximab vedotin; immune checkpoint inhibitors; nivolumab; pembrolizumab